Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp. is a biotechnology company specializing in the research, development, manufacture, and sale of advanced medical testing reagents and diagnostic technology. The company's primary focus is on in vitro diagnostic solutions, especially for early detection and monitoring of chronic diseases such as diabetes-related complications, chronic kidney diseases, and various cancers. Bio Preventive Medicine Corp. is known for its proprietary, clinically validated non-invasive tests like the DNlite series, which are designed to aid in managing diabetic nephropathy and help reduce the long-term burden of advanced kidney disease. Rooted in a foundation of biomarker-based innovation, the company emerged as a spin-off from the Industrial Technology Research Institute (ITRI) and leverages technology licensed from prestigious biomarker research initiatives in Taiwan. The company provides comprehensive prevention, screening, and monitoring solutions for both clinical laboratories and healthcare providers, supporting the global movement towards precision and preventive medicine. Its market presence extends across North America, Europe, Asia, and South America, underscoring its role as a key player in global healthcare technology advancements and the ongoing efforts to address unmet clinical needs in chronic disease management.